<DOC>
	<DOCNO>NCT02186249</DOCNO>
	<brief_summary>The purpose study provide treatment nivolumab combination ipilimumab subject anti- ( CTLA ) -4 anti-PD-1 treatment-naive unresectable metastatic melanoma .</brief_summary>
	<brief_title>Expanded Access Program With Nivolumab Combination With Ipilimumab Patients With Tumors Unable Removed Surgery Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Men woman 18 year old Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Histologicallyconfirmed unresectable stage III stage IV melanoma , per American Joint Committee Cancer ( AJCC ) stag system , Including mucosal ocular melanoma Subjects must antiCTLA4 treatmentnaive antiPD1 treatmentnaive . Subjects may prior systemic treatment localize metastatic disease Subjects brain metastasis eligible treated magnetic resonance imaging ( MRI ) evidence progression least 2 week treatment complete within 28 day prior first dose study drug administration . There must also requirement high dos systemic corticosteroid could result Immunosuppression ( &gt; 10 mg/day prednisone equivalent ) least 2 week prior study drug administration Active ( symptomatic ) treat brain metastasis leptomeningeal metastasis Life expectancy &lt; 6 week Subjects active , know , suspect autoimmune disease . Subjects Type I diabetes mellitus , hypothyroidism require hormone replacement , skin disorder ( vitiligo , psoriasis , alopecia ) require systemic treatment , condition expect recur absence external trigger permit enroll Subjects condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day treatment . Inhaled topical steroid adrenal replacement steroid dose &gt; 10 mg daily prednisone equivalent permit absence active autoimmune disease Subjects receive prior therapy antiCTLA4 , antiPD1 , antiPDL1 antiPDL2 , antiCT137 ( antibody drug specifically target Tcell costimulation checkpoint pathway ) subject expect require form systemic antineoplastic therapy receiving nivolumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>